Off-Label Promotion Not Enough For Fed Intervention – Patton Boggs Lawyer
This article was originally published in The Gray Sheet
Executive Summary
Promotion of off-label applications alone will rarely trigger a U.S. Department of Justice investigation of a drug or device manufacturer, according to Patton Boggs partner Laura Laemmle
You may also be interested in...
High-Revenue Products Used Off-Label May Draw Scrutiny – Ex-DoJ Lawyer
Companies with high-ticket products being used off-label are more vulnerable to government enforcement actions for off-label promotional activities, according to Sonnenschein, Nath & Rosenthal partner T. Reed Stephens
High-Revenue Products Used Off-Label May Draw Scrutiny – Ex-DoJ Lawyer
Companies with high-ticket products being used off-label are more vulnerable to government enforcement actions for off-label promotional activities, according to Sonnenschein, Nath & Rosenthal partner T. Reed Stephens
Serono And RJL Systems Plead Guilty To AIDS Drug And Device Fraud
Serono Labs will plead guilty to criminal charges that it offered kickbacks to doctors and conspired with medical device maker RJL Sciences to market an unapproved diagnostic device in order to increase sales of its drug Serostim, used to treat AIDS wasting